SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-105351
Filing Date
2023-09-29
Accepted
2023-09-29 16:39:07
Documents
14
Period of Report
2023-09-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2327232d1_8k.htm   iXBRL 8-K 29951
2 EXHIBIT 1.1 tm2327232d1_ex1-1.htm EX-1.1 230189
3 EXHIBIT 5.1 tm2327232d1_ex5-1.htm EX-5.1 8976
  Complete submission text file 0001104659-23-105351.txt   505059

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA trda-20230929.xsd EX-101.SCH 3018
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE trda-20230929_lab.xml EX-101.LAB 34240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE trda-20230929_pre.xml EX-101.PRE 22361
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2327232d1_8k_htm.xml XML 3423
Mailing Address ONE DESIGN CENTER PLACE SUITE 17-500 BOSTON MA 02210
Business Address ONE DESIGN CENTER PLACE SUITE 17-500 BOSTON MA 02210 857-305-1825
Entrada Therapeutics, Inc. (Filer) CIK: 0001689375 (see all company filings)

IRS No.: 813983399 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40969 | Film No.: 231296281
SIC: 2834 Pharmaceutical Preparations